ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

0J7G Hutchison China Meditech Ltd

33.29
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech Ltd LSE:0J7G London Ordinary Share HUTCHISON CHINA MEDITECH ADR REPRESENTIN
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 33.29 98 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 838M 100.78M - N/A 0

Hutchison China Meditech Limited Annual Report & Notice of Annual General Meeting (8420I)

26/03/2018 7:00am

UK Regulatory


Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Hutchison China Meditech Charts.

TIDMHCM

RNS Number : 8420I

Hutchison China Meditech Limited

26 March 2018

2017 Annual Report and

Notice of Annual General Meeting

London: Monday, March 26, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.chi-med.com).

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President, Corporate 
 Finance & Development                       +852 2121 8200 
 
U.K. & International Media Enquiries 
Anthony Carlisle, Citigate Dewe Rogerson     +44 7973 611 888 (Mobile)   anthony.carlisle@cdrconsultancy.co.uk 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications               +1 (917) 570 7340 (Mobile)  bmiles@bmccommunications.com 
Susan Duffy, BMC Communications              +1 (917) 499 8887 (Mobile)  sduffy@bmccommunications.com 
 
Investor Relations 
Matt Beck, The Trout Group                   +1 (917) 415 1750 (Mobile)  mbeck@troutgroup.com 
David Dible, Citigate Dewe Rogerson          +44 7967 566 919 (Mobile)   david.dible@citigatedewerogerson.com 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts                  +44 (20) 7886 2500 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSPGUQAWUPRPUA

(END) Dow Jones Newswires

March 26, 2018 02:00 ET (06:00 GMT)

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Your Recent History

Delayed Upgrade Clock